Activated Clotting Time Testing Market to reach USD 643.93 million by 2030, Size, Trends

The activated clotting time (ACT) is a test that is utilized mainly to monitor high doses of unfractionated (standard) heparin therapy. Heparin is a drug that prevents the blood clotting (anticoagulant) and is generally given intravenously (IV) by injection or by continuous infusion. High doses of heparin may be given during processes that require the blood to be prevented from clotting, like the heart bypass surgery.

View Detailed Report" https://www.databridgemarketresearch.com/reports/global-activated-clotting-time-testing-market

The incidence of coagulation disorders like disseminated intravascular coagulation (DIC) varies depending on the underlying condition. For example, in patients with sepsis, the incidence of DIC ranges from 20% to 50%. The annual incidence of Deep vein thrombosis (DVT) is estimated to be around 1 to 2 cases per 1,000 individuals, while the annual incidence of pulmonary embolism (PE) is approximately 0.5 to 1 case per 1,000 individuals. The incidence of haemophilia A is estimated to be around 1 in 5,000 to 10,000 male births, while the incidence of haemophilia B is lower, at approximately 1 in 30,000 male births.

Opportunities

Increasing Adoption of Point-of-Care Testing

Point-of-care testing (POCT) is gaining popularity due to its ability to provide immediate results at the patient's bedside or in outpatient settings. ACT testing at the point of care offers the opportunity for rapid and real-time monitoring of clotting time, enabling prompt adjustments in anticoagulant therapy and reducing the risk of bleeding or thrombotic events.

Advances in Technology and Automation

Technological advancements in ACT testing devices, including the development of automated systems, provide opportunities for improved accuracy, speed, and ease of use. Automation reduces human error, streamlines workflow, and enhances efficiency in ACT testing laboratories, thereby increasing adoption and demand for ACT testing.

Drivers

Increasing Prevalence of Cardiovascular Diseases

Cardiovascular diseases, such as atrial fibrillation, deep vein thrombosis, and coronary artery disease, are major contributors to morbidity and mortality worldwide. The need for accurate and timely monitoring of clotting time in patients with these conditions drives the demand for ACT testing.

Growing Demand for Anticoagulant Therapy

Anticoagulant medications, including heparin, are commonly used in the management and prevention of blood clotting disorders. ACT testing is essential to monitor the effectiveness and safety of anticoagulant therapy, ensuring that patients are within the desired therapeutic range.

Some of the major players operating in the global activated clotting time testing market are:

F. Hoffmann-La Roche Ltd (Switzerland)

Siemens (Germany)

Thermo Fisher Scientific (U.S.)

Abbott (U.S.)

Helena Laboratories Corporation (U.S.)

Sysmex Corporation (Japan)

NIHON KOHDEN CORPORATION (Japan)

Instrumentation Laboratory India Pvt ltd (India)

Medtronic (Ireland)

Diagnostica Stago S.A.S (France)

Browse More Reports:

https://dbmrresearchreports.blogspot.com/2024/04/compression-therapy-market-to-reach-usd.html

https://dbmrresearchreports.blogspot.com/2024/04/liquid-packaging-board-market-will-grow.html

https://dbmrresearchreports.blogspot.com/2024/04/managed-network-services-market-to.html

https://dbmrresearchreports.blogspot.com/2024/04/polystyrene-market-registering-cagr-of.html

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact Us:

Data Bridge Market Research
Tel: +1-888-389.80-2818 | +44 208 089 1725 | +852 8192 7475
Email: Corporatesales@databridgemarketresearch.com

This release was published on openPR.